Compare Biogen Inc (BIIB) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs US Bancorp — how do they compare? Biogen Inc trades at $202.7 (market cap $30.13B), while US Bancorp trades at $64.31 (market cap $100.17B). The key difference: US Bancorp is far larger — about 3.3× Biogen Inc's market cap, and US Bancorp pays a 3.24% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | USB | |
|---|---|---|
Market Cap | $30.13B | $100.17B |
Sector | Health | Financials |
52-Week High | $216.63 | $64.47 |
52-Week Low | $128.93 | $45.28 |
Enterprise Value | $37.20B | — |
Dividend Yield | — | 3.24% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
